sur BioVersys AG
BioVersys AG Annual General Meeting Yields Positive Outcomes
BioVersys AG announced the outcomes of its Annual General Meeting (AGM) of Shareholders held on June 27, 2025. A noteworthy 55.4% of the company's share capital was represented. All agenda items secured a majority vote in favor.
The AGM approved the 2024 Annual Report, re-elected key board members including Seng Chin Mah as Chairman, and elected Ulrik Schulze as a new board member. Additionally, shareholders endorsed an amendment to the company's capital structure, enhancing the board’s operational flexibility for strategic initiatives.
Chairman Seng Chin Mah expressed gratitude to shareholders for their unwavering support as the company approaches the final development phase for BV100 and progresses with alpibectir and preclinical projects. He also welcomed Dr. Ulrik Schulze to the board.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de BioVersys AG